翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年7月9日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | | 於上海證券交易所上市 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | 每股發行/出售價 (註4) | 已 ...

Individual Company News - Ocean Power announced that the company is planning to issue shares overseas (H-shares) and list on the Hong Kong Stock Exchange [1] - BlackRock's holding in Lenovo Group (00992.HK) decreased from 5.53% on July 2 to 4.94% [2] - BlackRock's holding in WuXi AppTec (02359.HK) decreased from 5.49% on July 2 to 4.98% [3] - Q Technology (01478.HK) reported that its mobile camera module sales reached 32.648 million units in June 2025, representing a year-on-year increase of 1.5% [4] - Lens Technology (06613.HK) saw its stock rise over 5% in the dark market, with an official listing on the main board of the Hong Kong Stock Exchange expected on July 9, 2025 [5]

港交所文件显示，贝莱德(BLK.N)在药明康德(02359.HK)H股持仓比例从7月2日的5.49%降至4.98%。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年7月7日 | 2,485,141,055 | | | 0 | | 2,485,141,055 | | 1). 其他 (請註明) | | | | ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年7月8日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 ...

Core Viewpoint - WuXi AppTec is actively enhancing shareholder value through A-share repurchase and H-share acquisition programs, aimed at attracting and retaining talent while maintaining company stability [1][2][3] A-Share Repurchase and Cancellation - The company repurchased and cancelled A-shares worth RMB1.0 billion to uphold its value and protect shareholder interests [2][3] - From April 18, 2025, to June 20, 2025, WuXi AppTec acquired 15,775,377 A-shares, approximately 0.55% of total issued share capital, at an average price of RMB63.39 per share [3] - The cancellation of all repurchased A-shares was completed on June 24, 2025 [3] H-Share Acquisition - WuXi AppTec instructed the Scheme Trustee to acquire HKD2.5 billion worth of H-shares to support the 2025 H Share Award and Trust Scheme [2][3] - A total of 34,092,975 H-shares were acquired, representing approximately 1.19% of total issued share capital, with no dilution to existing shareholders [3] - The H-share acquisition aims to attract and retain top talent, enhancing management capabilities and business resilience [3] H Share Award and Trust Scheme - Under the scheme, up to HKD1.5 billion worth of H-shares will be granted if the company's 2025 revenue reaches at least RMB42.0 billion [3] - An additional HKD1.0 billion worth of H-shares will be granted if the revenue reaches at least RMB43.0 billion, totaling HKD2.5 billion [3]

Group 1 - The A-share market showed mixed results with the Chinese Securities Trading Service Hong Kong Biotechnology Index (CESHKB) declining by 2.61% to 7650.23 points, with a trading volume of 9.469 billion [1] - Over the past month, the CESHKB has increased by 15.23%, 28.86% over the last three months, and 75.31% year-to-date [1] - The CESHKB is compiled by the China Securities Index Co., Ltd. under the commission of the China Securities Trading Service Co., Ltd., aiming to reflect the overall performance of biotechnology companies listed in Hong Kong [1] Group 2 - The top ten holdings of the CESHKB include: CanSino Biologics (12.33%), Innovent Biologics (9.95%), WuXi Biologics (9.17%), 3SBio (8.66%), BeiGene (8.57%), Zai Lab (5.79%), WuXi AppTec (5.63%), Kelun-Biotech (5.28%), Ascentage Pharma-B (4.19%), and Kingstar Biotech (4.11%) [1] - The CESHKB's holdings are entirely composed of companies listed on the Hong Kong Stock Exchange, with a 100% representation in the healthcare sector [2]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年7月7日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 第 1 頁 共 8 頁 v 1.3.0 | 1). | 購回股份(或其他證券)但沒有註銷 | 302,500 | 0.01 % | RMB | 66.14 | | --- | --- | --- | --- | --- | --- | | | 茲提述本公司於2025年3月17日刊發的公告，於2025年3月26日刊發的 | | | | | | | 通函，及於2025年4月29日刊發的投票結果公告。 | | | | | | | 於2025年6月26日，本公司實施2025年以集中競價交易方式回購本公司 | | | | | | | A ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年7月7日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 | 佔有關事件前的現有已發 行股份（不包括庫存股 | 庫存股份數目 ...

Group 1 - The Hong Kong stock market's biopharmaceutical sector experienced significant declines in early trading, with Rongchang Biopharmaceutical (09995.HK) dropping over 5% [1] - WuXi AppTec (02268.HK) and WuXi Biologics (02269.HK) both fell by more than 4% [1] - Other companies such as Innovent Biologics (09969.HK) and WuXi AppTec (02359.HK) also saw declines [1] Group 2 - The decline in the biopharmaceutical sector is attributed to the passage of the "Big Beautiful Act" in the U.S., which proposes cuts to healthcare spending [1]